Renal Cell Cancer An Issue Of Hematology Oncology Clinics Of North America E Book

In this issue of Hematology/Oncology Clinics, guest editors Drs. Bradley A. McGregor and Toni K. Choueiri bring their considerable expertise to the topic of Renal Cell Cancer. Top experts in the field cover key topics such as VHL and HIF at the center of renal cell cancer biology; immunobiology and metabolic pathways of renal cell cancer; hereditary renal cell cancer syndromes; the role of the pathologist in renal cell cancer; novel imaging in renal cell cancer; and more. Contains 18 relevant, practice-oriented topics including the role of surgery in metastatic renal cell cancer; emerging biomarkers in metastatic renal cell cancer; choosing the right treatment for renal cell cancer of variant histology; novel targets in the treatment of renal cell cancer; and more. Provides in-depth clinical reviews on renal cell cancer, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

In this issue of Hematology/Oncology Clinics, guest editors Drs. Bradley A. McGregor and Toni K. Choueiri bring their considerable expertise to the topic of Renal Cell Cancer. Top experts in the field cover key topics such as VHL and HIF at the center of renal cell cancer biology; immunobiology and metabolic pathways of renal cell cancer; hereditary renal cell cancer syndromes; the role of the pathologist in renal cell cancer; novel imaging in renal cell cancer; and more. Contains 18 relevant, practice-oriented topics including the role of surgery in metastatic renal cell cancer; emerging biomarkers in metastatic renal cell cancer; choosing the right treatment for renal cell cancer of variant histology; novel targets in the treatment of renal cell cancer; and more. Provides in-depth clinical reviews on renal cell cancer, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Topics for this issue will include: Epidemiology of RCC;New Insights into the Biology of RCC;Pathology of Renal Neoplasms;Imaging in RCC;Small Renal Tumors: Prognosis and Management;The Role of Surgery in the management of RCC: Nephrectomy and metastatectomy;Cytoreductive Nephrectomy: Rationale and current Applications;Adjuvant Therapies in RCC and Management of Side Effects from Current Therapies in RCC

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. Guru P. Sonpavde, is devoted to Bladder Cancer. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Epidemiology of bladder cancer, The molecular biology of bladder cancer and potential implications for therapy, Current therapy for metastatic urothelial carcinoma, Current perioperative therapy for muscle invasive urothelial carcinoma, Current therapy and emerging intravesical agents to treat non-muscle invasive bladder cancer, Diagnosis and staging of bladder and upper tract urothelial cancer, Surgery for bladder and upper tract urothelial cancer, Bladder conserving therapy for muscle invasive bladder cancer: opportunities to incorporate molecular profiling, Emerging immunotherapy for bladder cancer, Emerging targeted therapy for bladder cancer, Real world outcomes of patients with bladder cancer, Preclinical systems to develop bladder cancer therapeutics, Developing precision medicine for bladder cancer, and Future Directions in Bladder Cancer Treatment and Research.

Topics include: Rare Cancers; Mast Cell Leukemia; Uveal Melanoma; Esthesioneuroblastoma; Parathyroid Carcinoma; Thymoma/Thymic Carcinoma; Mesothelioma; Gastrointestinal Stromal Tumor (GIST); Uterine Sarcoma; Cancer of the Appendix; Urethral Cancer; Anal Cancer; and Merkel Cell Carcinoma.

Topics include: Why does my patient have leukocytosis?, Why Is My Patient Neutropenic?, Does My Patient with a Serum Monoclonal Spike have Multiple Myeloma?, DVT and Pulmonary Embolism, Why Does My Patient Have Lymphadenopathy/Splenomegaly?,and Why Does My Patient have Thrombocytopenia?

In this issue of Urologic Clinics of North America, guest editors Drs. Michael L. Blute and Steven L. Chang bring their considerable expertise to the topic of Renal Cancer: Old and New Paradigms. Recent significant advances in the management of renal cancer have expanded beyond simply eliminating disease to preserving and optimizing quality of life. In this issue, top experts highlight historical perspectives as well as current status and future treatments of renal cancer. Contains 13 practice-oriented topics on biomarkers for the detection and surveillance of renal cancer; the changing role of renal mass biopsy; renal cysts: an oncological conundrum; the surgical management of renal cancer with inferior vena caval thrombus; integrating surgery in the multidisciplinary care of advanced renal cancer; and more. Provides in-depth clinical reviews on renal cancer, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This issue of Hematology/Oncology Clinics of North America, guest edited by Dr. Joaquin Bellmunt, is devoted to Bladder Cancer. Articles in this issue include: Diagnosis and Staging of Bladder Cancer; Epidemiology of Bladder Cancer; Molecular Biology of Bladder Cancer; Pharmacogenomics in Bladder Cancer; Management of Non-muscle Invasive Bladder Cancer; Non-urothelial Bladder Cancer and Rare Variant Histologies; Management of UUT; New Trends in Surgical Management of Bladder Cancer; Bladder Preservation Strategies; Perioperative Therapy of Bladder Cancer (Neoadjuvant and Adjuvant); First Line Treatment and Prognostic Factors of Metastatic Disease: Platinum Eligible Patients; First Line Treatment of Metastatic Disease: Platinum Ineligible Patients; Salvage Therapy in Metastatic Disease; and Future Directions and Targeted Therapies in Bladder Cancer.